These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

945 related articles for article (PubMed ID: 7714115)

  • 1. Somatostatin receptor subtype gene expression in pituitary adenomas.
    Miller GM; Alexander JM; Bikkal HA; Katznelson L; Zervas NT; Klibanski A
    J Clin Endocrinol Metab; 1995 Apr; 80(4):1386-92. PubMed ID: 7714115
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Somatostatin receptor subtype 1 selective activation in human growth hormone (GH)- and prolactin (PRL)-secreting pituitary adenomas: effects on cell viability, GH, and PRL secretion.
    Zatelli MC; Piccin D; Tagliati F; Ambrosio MR; Margutti A; Padovani R; Scanarini M; Culler MD; degli Uberti EC
    J Clin Endocrinol Metab; 2003 Jun; 88(6):2797-802. PubMed ID: 12788890
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Somatostatin receptor-specific analogs: effects on cell proliferation and growth hormone secretion in human somatotroph tumors.
    Danila DC; Haidar JN; Zhang X; Katznelson L; Culler MD; Klibanski A
    J Clin Endocrinol Metab; 2001 Jul; 86(7):2976-81. PubMed ID: 11443154
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of somatostatin receptor (SSTR) subtypes in pituitary adenomas: quantitative analysis of SSTR2 mRNA by reverse transcription-polymerase chain reaction.
    Murabe H; Shimatsu A; Ihara C; Mizuta H; Nakamura Y; Nagata I; Kikuchi H; Nakao K
    J Neuroendocrinol; 1996 Aug; 8(8):605-10. PubMed ID: 8866248
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Somatostatin receptor subtype specificity in human fetal pituitary cultures. Differential role of SSTR2 and SSTR5 for growth hormone, thyroid-stimulating hormone, and prolactin regulation.
    Shimon I; Taylor JE; Dong JZ; Bitonte RA; Kim S; Morgan B; Coy DH; Culler MD; Melmed S
    J Clin Invest; 1997 Feb; 99(4):789-98. PubMed ID: 9045884
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pituitary and hypothalamic somatostatin receptor subtype messenger ribonucleic acid expression in the food-deprived and diabetic rat.
    Bruno JF; Xu Y; Song J; Berelowitz M
    Endocrinology; 1994 Nov; 135(5):1787-92. PubMed ID: 7956902
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Somatostatin receptor subtypes mRNA in TSH-secreting pituitary adenomas: a case showing a dramatic reduction in tumor size during short octreotide treatment.
    Horiguchi K; Yamada M; Umezawa R; Satoh T; Hashimoto K; Tosaka M; Yamada S; Mori M
    Endocr J; 2007 Jun; 54(3):371-8. PubMed ID: 17420609
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human somatostatin receptor subtypes in acromegaly: distinct patterns of messenger ribonucleic acid expression and hormone suppression identify different tumoral phenotypes.
    Jaquet P; Saveanu A; Gunz G; Fina F; Zamora AJ; Grino M; Culler MD; Moreau JP; Enjalbert A; Ouafik LH
    J Clin Endocrinol Metab; 2000 Feb; 85(2):781-92. PubMed ID: 10690891
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of the intracellular mechanisms mediating somatostatin and lanreotide inhibition of DNA synthesis and growth hormone release from dispersed human GH-secreting pituitary adenoma cells in vitro.
    Florio T; Thellung S; Corsaro A; Bocca L; Arena S; Pattarozzi A; Villa V; Massa A; Diana F; Schettini D; Barbieri F; Ravetti JL; Spaziante R; Giusti M; Schettini G
    Clin Endocrinol (Oxf); 2003 Jul; 59(1):115-28. PubMed ID: 12807513
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pre-clinical and clinical experiences with novel somatostatin ligands: advantages, disadvantages and new prospects.
    Hofland LJ; van der Hoek J; Feelders R; van der Lely AJ; de Herder W; Lamberts SW
    J Endocrinol Invest; 2005; 28(11 Suppl International):36-42. PubMed ID: 16625843
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of three somatostatin receptor subtypes in pituitary adenomas: evidence for preferential SSTR5 expression in the mammosomatotroph lineage.
    Greenman Y; Melmed S
    J Clin Endocrinol Metab; 1994 Sep; 79(3):724-9. PubMed ID: 7521350
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of somatostatin receptor subtypes and an implication for the efficacy of somatostatin analogue SMS 201-995 in treatment of human endocrine tumors.
    Kubota A; Yamada Y; Kagimoto S; Shimatsu A; Imamura M; Tsuda K; Imura H; Seino S; Seino Y
    J Clin Invest; 1994 Mar; 93(3):1321-5. PubMed ID: 8132773
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantitative analysis of somatostatin receptor subtype (SSTR1-5) gene expression levels in somatotropinomas and non-functioning pituitary adenomas.
    Taboada GF; Luque RM; Bastos W; Guimarães RF; Marcondes JB; Chimelli LM; Fontes R; Mata PJ; Filho PN; Carvalho DP; Kineman RD; Gadelha MR
    Eur J Endocrinol; 2007 Jan; 156(1):65-74. PubMed ID: 17218727
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Somatostatin receptors in pituitary and development of somatostatin receptor subtype-selective analogs.
    Shimon I
    Endocrine; 2003 Apr; 20(3):265-9. PubMed ID: 12721506
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pasireotide, a multiple somatostatin receptor subtypes ligand, reduces cell viability in non-functioning pituitary adenomas by inhibiting vascular endothelial growth factor secretion.
    Zatelli MC; Piccin D; Vignali C; Tagliati F; Ambrosio MR; Bondanelli M; Cimino V; Bianchi A; Schmid HA; Scanarini M; Pontecorvi A; De Marinis L; Maira G; degli Uberti EC
    Endocr Relat Cancer; 2007 Mar; 14(1):91-102. PubMed ID: 17395978
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of mRNA for all five human somatostatin receptors (hSSTR1-5) in pituitary tumors.
    Panetta R; Patel YC
    Life Sci; 1995; 56(5):333-42. PubMed ID: 7530798
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Somatostatin receptor (SSTR) subtype-selective analogues differentially suppress in vitro growth hormone and prolactin in human pituitary adenomas. Novel potential therapy for functional pituitary tumors.
    Shimon I; Yan X; Taylor JE; Weiss MH; Culler MD; Melmed S
    J Clin Invest; 1997 Nov; 100(9):2386-92. PubMed ID: 9410919
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of somatostatin receptors on human pituitary adenomas in vivo and ex vivo.
    Nielsen S; Mellemkjaer S; Rasmussen LM; Ledet T; Olsen N; Bojsen-Møller M; Astrup J; Weeke J; Jørgensen JO
    J Endocrinol Invest; 2001 Jun; 24(6):430-7. PubMed ID: 11434667
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The novel somatostatin analog SOM230 is a potent inhibitor of hormone release by growth hormone- and prolactin-secreting pituitary adenomas in vitro.
    Hofland LJ; van der Hoek J; van Koetsveld PM; de Herder WW; Waaijers M; Sprij-Mooij D; Bruns C; Weckbecker G; Feelders R; van der Lely AJ; Beckers A; Lamberts SW
    J Clin Endocrinol Metab; 2004 Apr; 89(4):1577-85. PubMed ID: 15070915
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential inhibition of growth hormone secretion by analogs selective for somatostatin receptor subtypes 2 and 5 in human growth-hormone-secreting adenoma cells in vitro.
    Tulipano G; Bonfanti C; Milani G; Billeci B; Bollati A; Cozzi R; Maira G; Murphy WA; Poiesi C; Turazzi S; Giustina A
    Neuroendocrinology; 2001 May; 73(5):344-51. PubMed ID: 11399907
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 48.